Cashing in on PhII trial success, Arena to raise $353M to fuel PhIII etrasimod/ralinepag trials
Taking advantage of its stock’s hot position this week, Arena $ARNA is following its promising Phase II data with a public offering that should bring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.